摘要 |
<p>Disclosed is a method for diagnosis of cancer, which is characterized by detecting an epiregulin (EREG) protein. It is found that the expression of an EREG is enhanced at a vary high frequency in a gene level or a protein level in gastrointestinal cancer, pulmonary adenocarcinoma, pancreatic cancer, gastric cancer or renal cancer. In the diagnosis or treatment of cancer, an antibody recognizing the EREG protein is used. Also disclosed are a pharmaceutical composition, a cell proliferation inhibitor and an anti-cancer agent, each comprising an antibody capable of binding to an EREG as an active ingredient. Further disclosed is a method for inducing cytopathy in an EREG-expressing cell or inhibiting the proliferation of an EREG-expressing cell, by contacting the EREG-expressing cell with an antibody capable of binding to an EREG.</p> |